- Trials with a EudraCT protocol (190)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
190 result(s) found for: endometrial cancer.
Displaying page 5 of 10.
EudraCT Number: 2004-003886-34 | Sponsor Protocol Number: CFEM345ADE08 | Start Date*: 2008-06-16 |
Sponsor Name:Novartis Pharma GmbH | ||
Full Title: Phase II study on letrozole in patients with advanced or recurrent hormone receptor positive endometrial cancer. | ||
Medical condition: endometrial cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-002079-93 | Sponsor Protocol Number: INCAGN1949-101 | Start Date*: 2017-07-17 | |||||||||||||||||||||||||||||||
Sponsor Name:Incyte Biosciences International Sàrl | |||||||||||||||||||||||||||||||||
Full Title: A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | |||||||||||||||||||||||||||||||||
Medical condition: Part 1: advanced or metastatic solid tumors Part 2: advanced or metastatic adenocarcinoma of the endometrium, ovarian cancer, renal cell carcinoma (RCC), melanoma, and non–small cell lung cancer (... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004752-34 | Sponsor Protocol Number: 53998 | Start Date*: 2019-02-20 |
Sponsor Name:Amsterdam University Medical Centers location AMC | ||
Full Title: Study of pembrolizumab combined with ataluren in Patients with metastatic pMMR and dMMR colorectal cancer adenocarcinomas or metastatic dMMR endometrial carcinoma: the ATAPEMBRO study. | ||
Medical condition: Mismatch repair deficient and proficient metestatic colorectal carcinoma and mismatch repair deficient metastatic endometrial carcinoma, stomach carcinoma and small bowel carcinoma. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004246-11 | Sponsor Protocol Number: EDO-S101-1002 | Start Date*: 2021-09-30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Mundipharma Research Limited | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients with Ad... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: • Cohort 1: Relapsed/refractory Small Cell Lung Cancer • Cohort 2: Relapsed/refractory Soft Tissue Sarcoma • Cohort 3: Relapsed/refractory Triple-Negative Breast Cancer • Cohort 4: Relapsed/refr... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Completed) IT (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-005610-37 | Sponsor Protocol Number: PROTEC1 | Start Date*: 2015-05-07 |
Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust | ||
Full Title: PROgesterone Therapy for Endometrial Cancer prevention in obese women (PROTEC) | ||
Medical condition: Proliferation of the endometrium. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003431-29 | Sponsor Protocol Number: CBGG492A2216 | Start Date*: 2014-05-27 |
Sponsor Name:Novartis Farma S.p.A. | ||
Full Title: A multicenter medical safety follow-up study for patients with partial onset seizures who received more than 28 days of total exposure to BGG492 in studies CBGG492A2207 and/or CBGG492A2212. | ||
Medical condition: Testing for adrenal cortical adenomas in male and female patients Testing for uterine endometrial stromal sarcromas in all female patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000518-40 | Sponsor Protocol Number: RAINBO-MMRd-GREEN-ENGOT-EC14_02 | Start Date*: 2022-01-17 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials - The MMRD-GREEN trial - | ||
Medical condition: Endometrial Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002824-26 | Sponsor Protocol Number: VHIO17001 | Start Date*: 2018-02-23 | |||||||||||
Sponsor Name:Vall d' Hebron Institute of Oncology (VHIO) | |||||||||||||
Full Title: Phase II trial of Pembrolizumab in combination with Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer (TOPIC) | |||||||||||||
Medical condition: Advanced, Recurrent or Metastatic Endometrial Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002429-37 | Sponsor Protocol Number: NSGO-EC-9501 Amendment 2 | Start Date*: 2004-11-17 |
Sponsor Name:Nordic Society for Gynecologic Oncology | ||
Full Title: A randomized trial of adjuvant treatment with radiation plus chemotherapy versus radiation alone in high-risk endometrial carcinoma NSGO-EC-9501 Amendment 2. | ||
Medical condition: Endometrial cancer stage I-III radically operated with high-risk factors (high-grade and deep myometrial infiltration, or serous or clear cell histology) that will receive adjuvant treatment with r... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-001290-78 | Sponsor Protocol Number: 007697 | Start Date*: 2012-01-17 |
Sponsor Name:Barts Health NHS Trust | ||
Full Title: Diagnostic accuracy of MRI, diffusion-weighted MRI, FDG-PET/CT and Fluoro-ethyl-choline PET/CT in the detection of lymph node metastases in surgically staged endometrial and cervical carcinoma | ||
Medical condition: Endometrial and Cervical Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-005018-76 | Sponsor Protocol Number: S60857 | Start Date*: 2019-01-14 |
Sponsor Name:University Hospitals Leuven | ||
Full Title: An open-label, single arm, prospective, multi-center, tandem two stage designed, phase II study to evaluate the efficacy of Fulvestrant in women with recurrent/metastatic estrogen receptor positive... | ||
Medical condition: endometrial stromal sarcoma uterine adenosarcoma endometrial carcinoma sex cord stromal tumors serous ovarian cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: BE (Completed) NL (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2011-003301-16 | Sponsor Protocol Number: 881/11 | Start Date*: 2012-04-27 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: A Randomized Phase II Trial of Carboplatin-Paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced (stage III-IV) or recurrent endometrial cancer. | |||||||||||||
Medical condition: endometrial cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000411-14 | Sponsor Protocol Number: 6639 | Start Date*: 2014-07-17 | |||||||||||
Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust | |||||||||||||
Full Title: A randomised double blind dose non-inferiority trial of a daily dose of 600mg versus 300mg versus 100mg of enteric coated aspirin as a cancer preventive in carriers of a germline pathological misma... | |||||||||||||
Medical condition: Lynch Syndrome also known as HNPCC (non hereditary non polyposis colorectal cancer). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FI (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003779-36 | Sponsor Protocol Number: ICR-CTSU/2018/10066 | Start Date*: 2019-10-11 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:The Institute of Cancer Research | ||||||||||||||||||||||||||||||||||||||
Full Title: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss | ||||||||||||||||||||||||||||||||||||||
Medical condition: Relapsed ovarian and endometrial clear cell carcinoma or relapsed other gynaecological cancers (endometriod (ovarian and endometrial), carcinosarcoma (ovarian and endometrial), cerviacal carcinoma ... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001185-10 | Sponsor Protocol Number: 14I/Prg02 | Start Date*: 2014-09-08 | |||||||||||
Sponsor Name:IBSA Institut Biochimique SA | |||||||||||||
Full Title: Effect of a progesterone 25 mg solution (Pleyris, IBSA Farmaceutici Italia, srl) administered by oral route compared to an oral progesterone 200 mg capsule (Prometrium, Rottapharm SpA) on the endom... | |||||||||||||
Medical condition: hormone replacement therapy of menopause (as progestin therapy in association to estrogen replacement therapy) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004302-63 | Sponsor Protocol Number: CLI20001/Lita005 | Start Date*: 2020-12-15 | |||||||||||
Sponsor Name:Litaphar Laboratorios S.L. | |||||||||||||
Full Title: A multi-centre, open-label, single-arm study assessing the safety and efficacy of 5 mg of mifepristone for the treatment of endometriosis in reproductive-age women during two treatment cycles of 24... | |||||||||||||
Medical condition: endometriosis in reproductive-age | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-005094-29 | Sponsor Protocol Number: AP23573-04-203 | Start Date*: 2006-02-13 | |||||||||||
Sponsor Name:ARIAD PHARMACEUTICALS,INC. | |||||||||||||
Full Title: A Phase II Study of AP23573, a mTOR Inhibitor, in Female Adult Patients with Recurrent or Persistent Endometrial Cancer | |||||||||||||
Medical condition: Treatment of Recurrent or Persistent Endometrial Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004575-12 | Sponsor Protocol Number: DOMEC | Start Date*: 2019-07-05 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: DOMEC - phase II trial of Durvalumab (MEDI4736) and Olaparib in Metastatic/recurrent Endometrial Cancer, a DGOG trial. | ||
Medical condition: advanced endometrial cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000275-16 | Sponsor Protocol Number: 2693-CL-0304 | Start Date*: 2019-09-03 | |||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. | |||||||||||||
Full Title: A Randomized, Placebo-controlled, Double-blind Phase 3 Clinical Study to Investigate the Long-Term Safety of Fezolinetant in Women Suffering from Vasomotor Symptoms (Hot Flashes) Associated with Me... | |||||||||||||
Medical condition: Vasomotor Symptoms (Hot Flashes) Associated with Menopause | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) LV (Completed) ES (Completed) CZ (Completed) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002540-26 | Sponsor Protocol Number: A/644/05 | Start Date*: 2006-02-16 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Evalutation of the effects of non pegylated liposomial doxorubicin MYOCET on the reduction of skin and cardiac toxicity in platinum resistant ovarian and endometrial cancer patients . A phase I... | |||||||||||||
Medical condition: second line treatment in platinum resistant ovarian and endometrial cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
